Recap: argenx Q3 Earnings

Shares of argenx ARGX decreased 6.1% in pre-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share were down 450.00% year over year to ($3.96), which missed the estimate of ($2.81).

Revenue of $8,968,000 declined by 5.78% year over year, which missed the estimate of $16,850,000.

Guidance

argenx hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

How To Listen To The Conference Call

Date: Oct 22, 2020

Time: 08:30 AM

ET Webcast URL: https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&referrer=https%3A%2F%2Fwww.argenx.com%2F&eventid=2738263&sessionid=1&key=F469E4B3D87911A523DAB8276C85E03C&regTag=&sourcepage=register

Recent Stock Performance

52-week high: $284.00

52-week low: $103.75

Price action over last quarter: Up 4.79%

Company Profile

argenx SE is a clinical stage biotechnology company. It is engaged in the business of developing a pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Its product pipeline includes product candidates such as ARGX-111, ARGX-109, ARGX-115, ARGX-112, and others. The company operates in the Netherlands, Germany, Denmark, Belgium, Switzerland, the United States, and Luxembourg. It derives the majority of its revenues from Switzerland.